A tumor-pH-responsive supramolecular photosensitizer for activatable photodynamic therapy with minimal in vivo skin phototoxicity

Theranostics

Volumn 7, Issue 10, 2017, Pages 2746-2756

  Li, Xingshu ^a,b   Zheng, Bi Yuan ^a   Ke, Mei Rong ^a   Zhang, Yongfan ^a   Huang, Jian Dong ^a   Yoon, Juyoung ^b  

^a FUZHOU UNIVERSITY   (China)

^b Ewha Womans University   (South Korea)

Author keywords

Activatable photosensitizer; Layered double hydroxide; Photodynamic therapy; Phthalocyanine; Skin phototoxicity

Indexed keywords

CATION; DERMATOLOGICAL AGENT; LAYERED DOUBLE HYDROXIDE OCTASULFONATE MODIFIED ZINC PHTHALOCYANINE; OCTASULFONATE MODIFIED ZINC PHTHALOCYANINE; PHOTOSENSITIZING AGENT; UNCLASSIFIED DRUG;

ACIDITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER INHIBITION; CANCER TISSUE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; FEMALE; FLUORESCENCE IMAGING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; PH; PHOTODYNAMIC THERAPY; PHOTODYNAMICS; PHOTOTOXICITY; PRECIPITATION; SKIN TOXICITY; STATIC ELECTRICITY; ANIMAL; CELL SURVIVAL; CONTACT DERMATITIS; DISEASE MODEL; DRUG EFFECTS; PHOTOCHEMOTHERAPY; PROCEDURES; SKIN; TREATMENT OUTCOME; TUMOR CELL LINE;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL SURVIVAL; DERMATITIS, PHOTOTOXIC; DISEASE MODELS, ANIMAL; HUMANS; HYDROGEN-ION CONCENTRATION; MICE; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; SKIN; TREATMENT OUTCOME;

EID: 85022212962     PISSN: None     EISSN: 18387640     Source Type: Journal    
DOI: 10.7150/thno.18861     Document Type: Article

References (61)

1. Brown SB, Brown EA, Wallker I. The present and future role of photodynamic therapy in cancer treatment. Lancet Oncol. 2004; 5: 497-508
2. Dolmans DE, Fukumura D, Jain RK. Photodynamic therapy for cancer. Nat Rev Cancer. 2003; 3: 380-7
3. Castano AP, Mroz P, Hamblin MR. Photodynamic therapy and anti-tumour immunity. Nat Rev Cancer. 2006; 6: 535-45
4. Celli JP, Spring BQ, Rizvi I, et al. Imaging and photodynamic therapy: mechanisms, monitoring, and optimization. Chem Rev. 2010; 110: 2795-838
5. Huang P, Lin J, Wang X, et al. Light-triggered theranostics based on photosensitizer-conjugated carbon dots for simultaneous enhanced-fluorescence imaging and photodynamic therapy. Adv Mater. 2012; 24: 5104-10
6. Turan IS, Yildiz D, Turksoy A, et al. A bifunctional photosensitizer for enhanced fractional photodynamic therapy: singlet oxygen generation in the presence and absence of light. Angew Chem Int Ed. 2016; 55: 2875-8
7. Wang C, Cheng L, Liu Y, et al. Imaging-guided pH-sensitive photodynamic therapy using charge reversible upconversion nanoparticles under near-infrared light. Adv Funct Mater. 2013; 23: 3077-86
8. Gong H, Chao Y, Xiang J, et al. Hyaluronidase to enhance nanoparticle-based photodynamic tumor therapy. Nano Lett. 2016; 16: 2512-21
9. Cheng Y, Cheng H, Jiang C, et al. Perfluorocarbon nanoparticles enhance reactive oxygen levels and tumour growth inhibition in photodynamic therapy. Nat Commun. 2015; 6: 8785-92
10. Zhuang X, Ma X, Xue X, et al. A photosensitizer-loaded DNA origami nanosystem for photodynamic therapy. ACS Nano. 2016; 10: 3486-95
11. Castano AP, Demidova TN, Hamblin MR, Mechanisms in photodynamic therapy: part two-cellular signaling, cell metabolism and modes of cell death. Photodiagnosis Photodyn Ther. 2005; 2: 1-23
12. Fan W, Huang P, Chen X. Overcoming the Achilles' heel of photodynamic therapy. Chem Soc Rev. 2016; 45: 6488-519
13. Gao W, Wang Z, Lv L, et al. Photodynamic therainduced enhancement of tumor vasculature permeability using an upconversion nanoconstruct for improved intratumoral nanoparticle delivery in deep tissues. Theranostics. 2016; 6: 1131-44
14. Yue C, Yang Y, Zhang C, et al. ROS-responsive mitochondria-targeting blended nanoparticles: chemo-and photodynamic synergistic therapy for lung cancer with on-demand drug release upon irradiation with a single light source. Theranostics. 2016; 6: 2352-66
15. Han K, Zhang WY, Zhang J, et al. Acidity-triggered tumor-targeted chimeric peptide for enhanced intra-nuclear photodynamic therapy. Adv Funct Mater. 2016; 26: 4351-61
16. Han D, Zhu G, Wu C, et al. Engineering a cell-surface aptamer circuit for targeted and amplified photodynamic cancer therapy. ACS Nano. 2013; 7: 2312-9
17. Huang Z. A review of progress in clinical photodynamic therapy. Technol Cancer Res Treat. 2005; 4: 283-93
18. Vrouenraets MB, Visser GW, Snow GB, et al. Basic principles, applications in oncology and improved selectivity of photodynamic therapy. Anticancer Res. 2003; 23: 505-22
19. Wang Y, Lin Y, Zhang H, et al. A photodynamic therapy combined with topical 5-aminolevulinic acid and systemic hematoporphyrin derivative is more efficient but less phototoxic for cancer. J Cancer Res Clin Oncol. 2016; 142: 813-21
20. Zhang Y, He L, Wu J, et al. Switchable PDT for reducing skin photosensitization by a NIR dye inducing self-assembled and photo-disassembled nanoparticles. Biomaterials. 2016; 107: 23-32
21. Schuh M, Nseyo UO, Potter WR, et al. Photodynamic therapy for palliation of locally recurrent breast carcinoma. J Clin Oncol. 1987; 5: 1766-70
22. Wyss P, Schwarz V, Dobler-Girdziunaite D, et al. Photodynamic therapy of locoregional breast cancer recurrences using a chlorin-type photosensitizer. Int J Cancer. 2001; 93: 720-4
23. Lovell JF, Liu TW, Chen J, et al. Activatable photosensitizers for imaging and therapy. Chem Rev. 2010; 110: 2839-57
24. Majumdar P, Nomula R, Zhao J. Activatable triplet photosensitizers: magic bullets for targeted photodynamic therapy. J Mater Chem C. 2014; 2: 5982-97
25. Lovell JF, Chan MW, Qi Q, et al. Porphyrin FRET acceptors for apoptosis induction and monitoring. J Am Chem Soc. 2011; 133: 18580-2
26. Kolemen S, Isik M, Kim GM, et al. Intracellular modulation of excited-state dynamics in a chromophore dyad: differential enhancement of photocytotoxicity targeting cancer cells. Angew Chem Int Ed. 2015; 54: 5340-44
27. Chen H, Tian J, He W, et al. H2O2-activatable and O2-evolving nanoparticles for highly efficient and selective photodynamic therapy against hypoxic tumor cells. J Am Chem Soc. 2015; 13: 1539-47
28. Kim H, Kim Y, Kim IH, et al. ROS-responsive activatable photosensitizing agent for imaging and photodynamic therapy of activated macrophages. Theranostics. 2014; 4: 1-11
29. Wu D, Song G, Li Z, et al. A two-dimensional molecular beacon for mRNA-activated intelligent cancer theranostics. Chem Sci. 2015; 6: 3839-44
30. Yuan Y, Zhang CJ, Gao M, et al. Specific light-up bioprobe with aggregation-induced emission and activatable photoactivity for the targeted and image-guided photodynamic ablation of cancer cells. Angew Chem Int Ed. 2015; 54: 1780-6
31. Ichikawa Y, Kamiya M, Obata F, et al. Selective ablation of ß-galactosidase-expressing cells with a rationally designed activatable photosensitizer. Angew Chem Int Ed. 2014; 53: 6772-5
32. Kim J, Tung CH, Choi Y. Smart dual-functional warhead for folate receptor-specific activatable imaging and photodynamic therapy. Chem Commun. 2014; 50: 10600-3
33. Fan H, Yan G, Zhao Z, et al. A smart photosensitizer-manganese dioxide nanosystem for enhanced photodynamic therapy by reducing glutathione levels in cancer cells. Angew Chem Int Ed. 2016; 55: 5477-82
34. Feng B, Zhou F, Xu Z, et al. Versatile prodrug nanoparticles for acid-triggered precise imaging and organelle-specific combination cancer therapy. Adv Funct Mater. 2016; 26: 7431-42
35. Durantini AM, Greene LE, Lincoln R, et al. Reactive oxygen species mediated activation of a dormant singlet oxygen photosensitizer: from autocatalytic singlet oxygen amplification to chemicontrolled photodynamic therapy. J Am Chem Soc. 2016; 138: 1215-25
36. Wang D, Wang T, Liu J, et al. Acid-activatable versatile micelleplexes for PD-L1 blockade-enhanced cancer photodynamic immunotherapy. Nano Lett. 2016; 16: 5503-13
37. Chen Q, Feng L, Liu J, et al. Intelligent albumin-MnO2 nanoparticles as pH-/H2O2-responsive dissociable nanocarriers to modulate tumor hypoxia for effective combination therapy. Adv Mater. 2016; 28: 7129-36
38. Wang Y, Zhou K, Huang G. A Nanoparticle-based strategy for the imaging of a broad range of tumours by nonlinear amplification of microenvironment signals. Nat Mater. 2014; 13: 204-12
39. Meng LB, Zhang W, Li D, et al. pH-Responsive supramolecular vesicles assembled by water-soluble pillar[5]arene and a BODIPY photosensitizer for chemo-photodynamic dual therapy. Chem Commun. 2015; 51: 14381-4
40. Tian J, Zhou J, Shen Z, et al. A pH-activatable and aniline-substituted photosensitizer for near-infrared cancer theranostics. Chem Sci. 2015; 6: 5969-77
41. Tian J, Ding L, Xu HJ, et al. Cell-specific and pH-activatable rubyrin-loaded nanoparticles for highly selective near-infrared photodynamic therapy against cancer. J Am Chem Soc. 2013; 135: 18850-8
42. Battogtokh G, Ko YT. Active-targeted pH-responsive albumin-photosensitizer conjugate nanoparticles as theranostic agents. J Mater Chem B. 2015; 3: 9349-59
43. Yuan Y, Kwok RT, Tang BZ, et al. Smart probe for tracing cancer therapy: selective cancer cell detection, image-guided ablation, and prediction of therapeutic response in situ. Small. 2015; 11: 4682-90
44. Lau JT, Lo PC, Jiang XJ, et al. A dual activatable photosensitizer toward targeted photodynamic therapy. J Med Chem. 2014; 57: 4088-97
45. Ke MR, Ng DK, Lo PC. A pH-responsive fluorescent probe and photosensitiser based on a self-quenched phthalocyanine dimer. Chem Commun. 2012; 48: 9065-7
46. Park SY, Baik HJ, Oh YT, et al. A smart polysaccharide/drug conjugate for photodynamic therapy. Angew Chem Int Ed. 2011; 50: 1644-7
47. He L, Li Y, Tan CP, et al. Cyclometalated iridium(III) complexes as lysosome-targeted photodynamic anticancer and real-time tracking agents. Chem Sci. 2015; 6: 5409-18
48. Braterman PS, Xu ZP, Yarberryin F. Handbook of layered materials. In: Auerbach SM, Carrado KA, Dutta PK, Ed. New York: Marcel Decker; 2004: 373-474
49. Xu ZP, Stevenson G., Lu CQ, et al. Stable suspension of layered double hydroxide nanoparticles in aqueous solution. J Am Chem Soc. 2006; 128: 36-7
50. Ladewig K, Xu ZP, Lu GQ. Layered double hydroxide nanoparticles in gene and drug delivery. Expert Opin Drug Del. 2009; 6: 907-22
51. Park DH, Cho J, Kwon OJ, et al. Biodegradable inorganic nanovector: passive versus active tumor targeting in siRNA transportation. Angew Chem Int Ed. 2016; 55: 4582-6
52. Liang RZ, Tian R, Ma LN, et al. A supermolecular photosensitizer with excellent anticancer performance in photodynamic therapy. Adv Funct Mater. 2014; 24: 3144-51
53. Choy JH, Kwak SY, Jeong YJ, et al. Inorganic layered double hydroxides as nonviral vectors. Angew Chem Int Edit. 2000; 39: 4041-45
54. Li XS, Ke MR, Huang W, et al. A pH-responsive layered double hydroxide (LDH)-phthalocyanine nanohybrid for efficient photodynamic therapy. Chem Eur J. 2015; 21: 3310-7
55. Li XS, Ke MR, Zhang MF, et al. A non-aggregated and tumour-associated macrophage-targeted photosensitiser for photodynamic therapy: a novel zinc(II) phthalocyanine containing octa-sulphonates. Chem Commun. 2015; 51: 4704-7
56. Darwent JR, Douglas P, Harriman A, et al. Metal phthalocyanines and porphyrins as photosensitizers for reduction of water to hydrogen. Coord Chem Rev. 1982; 44: 83-126
57. Novell JF, Chen J, Jarvi MT, et al. FRET quenching of photosensitizer singlet oxygen generation. J Phys Chem B. 2009; 113: 3203-11
58. Helmlinger G, Sckell A, Dellian M, et al. Acid production in glycolysis-impaired tumors provides new insights into tumor metabolism. Clin Cancer Res. 2002; 8: 1284-91
59. Jahde E, Glusenkamp KH, Rajewsky MF. Nigericin enhances mafosfamide cytotoxicity at low extracellular pH. Cancer Chemother Pharmacol. 1991; 27: 440-4
60. Jiang XJ, Lo PC, Yeung SL, et al. A pH-responsive fluorescence probe and photosensitiser based on a tetraamino silicon(IV) phthalocyanine. Chem Commun. 2010; 46: 3188-90
61. Liu W, Chen N, Jin H, et al. Intravenous repeated-dose toxicity study of ZnPcS2P2-based-photodynamic therapy in beagle dogs. Toxicol Pharmacol. 2007; 47: 221-31